About Us

Archives






Global Cell and Gene Therapy Market to Reach $25.00 Billion by 2027, Reports BIS Research – PRNewswire

Posted: February 25, 2021 at 6:48 am


FREMONT, Calif., Feb. 25, 2021 /PRNewswire/ -- The premium market intelligence report published by BIS Research titled Global Cell and Gene Therapy Markethighlights that the market is projected to reach $25.00 billion by the end of 2027. The study also highlights that the market is set to witness a CAGR of 33.82% during 2021-2027.The growth is attributed to increasing incidences of cancer and other chronic diseases, and the increasing number of clinical trials, among others.

Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry. However, the technology for manufacturing these therapies is still at a nascent stage. The cell and gene therapy market further continues to add new players within the industry. With over 1000 clinical trials performed, the field is becoming more promising with time.

Browse 10 Market Data Tables and 169 Figures spread through 285 Pages and in-depth TOC on "Global Cell and Gene Therapy Market"

The comprehensive study covers the following:

Who Should Buy This Report?

Besides these parameters, the study also encompasses market restraining factors, competition mapping, segmental analysis, and brief analysis of available drugs and FDA-approved cell and gene therapies in each therapeutic class in the last few years.

BIS Research study indicates that the increasing number of cell and gene therapies are in demand with driving factors such as increasing funding and investment in cell and gene therapies, and favorable regulatory environment and FDA approvals for cell and gene therapy products propelling the growth of the market.

View the Report on BIS Research - Global Cell and Gene Therapy Market

The study also highlights the various emerging opportunities for the market, such asthe rising number of drug approvals, a strong pipeline of cell and gene therapies, and an increasing number of mergers and acquisitions between companies operating in the cell and gene therapy market. The market intelligence report by BIS Research additionally throws a spotlight on the key industry restrains that are expected to have an influence in hampering the growth of the industry in the future.

In order to gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include product analysis, types of therapeutic class, pipeline analysis, region, and country. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study. The product analysis of the global market includes data analysis on the cell and gene therapies approved along with the therapeutic class analysis.

Gene and cell therapy is the use of genes and cells for the treatment of genetic diseases. Genetic diseases are caused by errors, or mutations, in genes that lead to a loss or modification of protein molecules. These mutations can be passed down from parents to children or can happen spontaneously. The advanced therapy medicinal products (ATMPs), brought in use to tackle these diseases, comprise ground-breaking cell and gene therapies (CGT) and tissue engineered (TE) products, which are the result of decades of research and development in the field of medicine.

Emphasizing the dominance of North America among all the regions in the market in 2020 and 2027, Nitish Kumar Singh, Principal Analyst BIS Research, states, "The therapy Zolgensma accounted for the largest share among all the cell and gene therapies, holding 13.96% of the global cell and gene therapy market in 2020. This segment is anticipated to grow at a significant CAGR during the forecast period 2021-2027. However, it is expected that the therapy Kymriah would witness the highest CAGR during the forecast period, 2021-2027."

Request for a Sample: https://bisresearch.com/requestsample?id=1062&type=download

Key insights have been drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon TissueGene, Inc., Organogenesis Holdings Inc., Pfizer, Inc., Renova Therapeutics, Shanghai Sunway Biotech Co. Ltd., and Sibiono GeneTech Co. Ltd.

The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

How can market intelligence on the cell and gene therapy market add value to an organization's decision-making process?

Insightful Questions Covered to Enable Companies to take Strategic Decisions

BIS Research Related Market Studies:

Global CRISPR Gene Editing Market - Analysis and Forecast, 2020-2030

About BIS Research:

BIS Researchis a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.

Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research offers syndicate as well as custom studies, and expert consultations to firms, providing them specific and actionable insights on novel technology markets, business models, and competitive landscape.

BIS Healthcare vertical offers intelligence in the healthcare technology market for Medical Devices, Digital Health, Life Sciences, Robotics and Imaging, Information Technology, Precision Medicine, and other emerging healthcare technologies, covering the entire industry spectrum. In the past five years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating Top 25 Voices in Precision Medicine on its Insight Monk platform for the past two years successfully.

Contact:Bhavya BangaEmail: [emailprotected] +1-510-404-8135BIS Research Inc.39111 PASEO PADRE PKWY STE 313,FREMONT CA 94538-1686Visit our Blog @ https://blog.bisresearch.com/ Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-researchConnect with us on [emailprotected] https://twitter.com/BISResearch

SOURCE BIS Research

Visit link:
Global Cell and Gene Therapy Market to Reach $25.00 Billion by 2027, Reports BIS Research - PRNewswire

Related Post

No Comments

No comments yet.

Sorry, the comment form is closed at this time.